Big Pharma vs Big Pharma in court battles over biosimilar drugs

Reuters, 2 October 2016
Author: John Miller
“The line dividing makers of brand-name drugs and copycat medicines is blurring as companies known for innovative treatments queue up to peddle copies of rivals’ complex biological medicines. These drugmakers are now increasingly straddling both sides of the courtroom, too, protecting their high-price products from biosimilars – biopharmaceutical drugs with the treatment properties of medicines they seek to mimic – while simultaneously challenging rivals’ patent claims.”
Find article here.